IQVIA (NYSE: IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment.

IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when seeking deep clinical and DCT implementation strategy expertise across therapeutics areas and phases, with over 200 DCT consultants, a wide portfolio of DCT-enabling technologies and services, and expertise in providing inputs on country-wise regulatory strategy for DCT implementation and on business process transformation for implementing a DCT model, as well as a focus on implementing healthcare-grade AI across the value chain, with novel GenAI tools to transform patient experience.”

“Call them what you may — decentralized trials, virtual trials, hybrid trials — DCTs are here to stay,” wrote Dr. Nimita Limaye, IDC’s research VP, Life Sciences R&D Strategy and Technology. “The focus is on integration, integration of technologies, integration of touch points to create unified and meaningful experiences, and the alignment of technologies and operating models. The way the industry is perceiving DCTs is maturing. No, DCTs aren’t going away. Instead, DCTs are becoming a 'business as usual' strategy today.”

Decentralized clinical trials, which gained popularity during the COVID-19 pandemic, are clinical trial studies that use telemedicine and mobile technologies to perform trial activities outside of a traditional clinical site. For example, patients can be monitored remotely using wearable devices, and the use of digital tools to communicate and collect data means patients are required to make fewer visits to trial sites.

IQVIA’s integrated strategy helps customers adopt, run and execute decentralized trial approaches, delivering a unique and differentiating experience.

"At IQVIA, we are proud to be a leader in decentralized clinical trials and remain focused on delivering cutting-edge technology solutions that enhance patient and site experiences and drive healthcare forward,” said Susan Hill, senior vice president, product management, Digital Products & Solutions at IQVIA.

"Being named a Leader in the IDC MarketScape report highlights our commitment to revolutionizing clinical trials through innovation and excellence. We are honored to receive this distinction and empower our customers to achieve outstanding results," said Alison Liddy, senior vice president for Patient and Site Centric Solutions at IQVIA.

This report is IDC’s first assessment of both DCT technology solutions and consulting services in life science R&D. The firm evaluated vendors’ capabilities, strategies and market success factors. Read the 2024 IDC MarketScape excerpt here.

About IQVIA

IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

About IDC MarketScape:

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250310714233/en/